ReviewKidney medicine2026
Glucose-only Therapy for Potassium Reduction: A Scoping Review.
Review in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin-dextrose therapy is widely used to manage hyperkalemia but carries a significant risk of iatrogenic hypoglycemia. Glucose alone may reduce serum potassium by stimulating endogenous insulin release, potentially offering an insulin sparing alternative. This scoping review examined studies evaluating the effect of oral or intravenous glucose, without concurrent insulin, on serum or plasma potassium in adults. Nonhuman studies, nonpeer-reviewed sources, and studies where diabetes status could not be determined were excluded. Of 1,105 records screened, 30 met inclusion criteria. Most studies were small and conducted before 2,000, involving healthy individuals and patients with various conditions. A narrative synthesis was performed, with findings categorized by diabetes status and intervention type. Potassium responses varied: in nondiabetic individuals, glucose-only therapy generally lowered potassium, often to a clinically meaningful extent. In contrast, potassium often rose in insulin-dependent individuals. Methodological limitations were common, including small sample sizes, inconsistent statistical reporting, lack of control groups, and limited inclusion of hyperkalemic patients. Although glucose-only therapy may be effective in nondiabetic populations, evidence in people with diabetes is inconsistent and the evidence base is limited. Further rigorous, controlled studies are needed to clarify the role of glucose-only therapy in hyperkalemia management and its impact on hypoglycemia risk. Plain-language Summary Hyperkalemia, a condition where there is too much potassium in the blood, is often treated with insulin and glucose. But insulin can cause low blood sugar (hypoglycemia), which can be harmful. This review examined whether using glucose alone-without insulin-could lower potassium safely. We found that in people without diabetes, glucose-only therapy often lowered potassium. But in people with diabetes, the results were mixed and, in some cases, potassium levels increased. Most studies included in this review were small and had design limitations, highlighting the need for further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.